16-FEB-2026 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 1 N 1 OBI-3424 8mg 67 5 0 0 0 0 0 02/08/2021 82 43
        2 OBI-3424 10mg   5 0 0 0 0 0      
        3 OBI-3424 12mg   14 6 3 0 0 0      
            24 6 3 0 0 0      
 
  S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 1 Delayed V-O 247 62 14 9 4 0 0 03/02/2021 277 94
        2 Early V-O   113 27 12 6 1 0      
            175 41 21 10 1 0      
 
  MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena 1 T 1 ASTX727 + Venetoclax + Enasidenib (Safety Run-in) 102 8 8 5 0 0 0 05/16/2025 213 59
            8 8 5 0 0 0      
 
  MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental 1 Y 1 Daunorubicin + Cytarabine 335 13 11 7 3 1 1 09/25/2024 301 103
        2 Venetoclax + Daunorubicin + Cytarabine   10 8 4 0 0 0      
        3 Venetoclax + Azacitidine   12 10 6 1 0 0      
        4 (Daunorubicin + Cytarabine) Liposome   13 11 7 2 1 1      
        5 (Daunorubicin + Cytarabine) Liposome + Venetoclax   9 8 3 1 1 1      
            57 48 27 7 3 3      
 
  MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials 1 Y 1 Screening   939 620 308 143 48 7 06/18/2024 365 137
            939 620 308 143 48 7      
 
    2 Y 2 Re-screening   92 69 39 23 12 8 06/18/2024    
            92 69 39 23 12 8      
 
    3 Y 3 Re-screening   25 23 16 5 3 2 06/18/2024    
            25 23 16 5 3 2      
 
    4 Y 4 Re-screening   2 2 1 1 0 0 06/18/2024    
            2 2 1 1 0 0      
 
Yes EA9213-T-ALL, dara-hyal for chemo refractory MRD 0 E Total Registrations   6 0 0 0 0 0 02/24/2023 115 39
            6 0 0 0 0 0      
 
    1 E Total Registrations   3 0 0 0 0 0 02/24/2023    
            3 0 0 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   71 0 0 0 0 0 11/09/2018 285 87
            71 0 0 0 0 0      
 
    1 E Total Registrations   57 0 0 0 0 0 11/09/2018    
            57 0 0 0 0 0      
 
    2 E Total Registrations   44 0 0 0 0 0 11/09/2018    
            44 0 0 0 0 0      
 
  A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 0 E Total Registrations   11 0 0 0 0 0 08/13/2020 166 51
            11 0 0 0 0 0      
 
    1 E Total Registrations   5 0 0 0 0 0 08/13/2020    
            5 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   66 16 8 3 2 0 02/19/2021 194 58
            66 16 8 3 2 0      
 
    1 E Total Registrations   54 13 6 3 2 0 02/19/2021    
            54 13 6 3 2 0      
 
    2 E Total Registrations   46 11 4 1 0 0 02/19/2021    
            46 11 4 1 0 0      
 
  MM1OA-EA02-MyeloMATCH: AML, New Dx, Ven+HMA 1 E Total Registrations   16 13 10 7 1 1 12/02/2024 301 100
            16 13 10 7 1 1      
 
  MM1YA-CTG01-MyeloMATCH: AML, New/Young/Int, Ven+Chemo 1 E Total Registrations   8 6 4 3 1 0 10/14/2024 37 7
            8 6 4 3 1 0      
 

16-FEB-2026 6:10

LEUK Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
21CTP.LEUK01 ALL, Ph+, Asciminib, Dasatinib and Prednisone 1 Initial Registration 15-May-25    
  2 Post-Remission 15-May-25    
  3 Maintenance 15-May-25    
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 3 Randomization 14-Oct-20 194 58

16-FEB-2026 6:10

LEUK Recently Closed Studies Accrual Report

OPEN Study Date
Closed		 Reg. Arm Total
Regs		 Regs
Last
30 Days		 Regs
Last
7 Days
N S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 15-Feb-26 1 1 OBI-3424 8mg 5 0 0
        2 OBI-3424 10mg 5 0 0
        3 OBI-3424 12mg 14 0 0